Seroprotection rate in adults after 1-dose, 2-dose, and 3-dose series of a reduced-diphtheria-tetanus toxoid vaccine (Td) during a diphtheria outbreak in Thailand

Vaccine ◽  
2020 ◽  
Vol 38 (9) ◽  
pp. 2128-2131 ◽  
Author(s):  
Piyarat Suntarattiwong ◽  
Warunee Punpanich Vandepitte ◽  
Pon Singhamatr ◽  
Tawee Chotpitayasunondh
Keyword(s):  
Tetanus Toxoid ◽  
Seroprotection Rate

scholarly journals Randomized, Controlled, Multicenter Study of the Immunogenicity and Safety of a Fully Liquid Combination Diphtheria–Tetanus Toxoid–Five-Component Acellular Pertussis (DTaP5), Inactivated Poliovirus (IPV), and Haemophilus influenzae Type b (Hib) Vaccine Compared with a DTaP3-IPV/Hib Vaccine Administered at 3, 5, and 12 Months of Age

2013 ◽  
Vol 20 (10) ◽  
pp. 1647-1653 ◽  
Author(s):  
Timo Vesikari ◽  
Sven Arne Silfverdal ◽  
Florence Boisnard ◽  
Stéphane Thomas ◽  
Grace Mwawasi ◽  
...  
Keyword(s):  
Haemophilus Influenzae ◽  
Tetanus Toxoid ◽  
Geometric Mean ◽  
Vaccination Schedule ◽  
Haemophilus Influenzae Type ◽  
Type B ◽  
Seroprotection Rate ◽  
Post Dose ◽  
Content Type ◽  
Robust Immune Response

ABSTRACTThis study compared the levels of immunogenicity and safety of diphtheria–tetanus toxoid–five-component acellular pertussis (DTaP5), inactivated poliovirus (IPV), andHaemophilus influenzaetype b (Hib) (DTaP5-IPV-Hib) and DTaP3-IPV/Hib vaccines for study participants 3, 5, and 12 months of age. Post-dose 3 noninferiority criteria comparing DTaP5-IPV-Hib to DTaP3-IPV/Hib using rates of seroprotection were demonstrated against diphtheria, tetanus, and polio types 1 to 3, but not for polyribosylribitol phosphate (PRP). While PRP did not meet noninferiority criteria, the seroprotection rate and geometric mean concentration (GMC) were high, indicating a clinically robust immune response. GMCs or titers for other antigens (including pertussis) and the safety profiles were generally similar between groups. Fully liquid DTaP5-IPV-Hib can be administered using the 3-, 5-, and 12-month vaccination schedule. (This study has been registered at ClinicalTrials.gov under registration no. NCT00287092.)

Delayed hypersensitivity to tetanus toxoid in man: in vivo and in vitro studies

Pathology ◽  
1983 ◽  
Vol 15 (4) ◽  
pp. 369-372 ◽  
Author(s):  
Christine Johnson ◽  
R.S. Walls ◽  
A. Ruwoldt
Keyword(s):  
Tetanus Toxoid ◽  
In Vitro Studies ◽  
Delayed Hypersensitivity

scholarly journals The Peptide Vaccine Combined with Prior Immunization of a Conventional Diphtheria-Tetanus Toxoid Vaccine Induced AmyloidβBinding Antibodies on Cynomolgus Monkeys and Guinea Pigs

2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Akira Yano ◽  
Kaori Ito ◽  
Yoshikatsu Miwa ◽  
Yoshito Kanazawa ◽  
Akiko Chiba ◽  
...  
Keyword(s):  
Immune Responses ◽  
Tetanus Toxoid ◽  
Guinea Pigs ◽  
Peptide Vaccine ◽  
Cell Epitope ◽  
T Cell Epitope ◽  
Peptide Vaccination ◽  
Binding Profile ◽  
Cynomolgus Monkeys ◽  
The Brain

The reduction of brain amyloid beta (Aβ) peptides by anti-Aβantibodies is one of the possible therapies for Alzheimer’s disease. We previously reported that the Aβpeptide vaccine including the T-cell epitope of diphtheria-tetanus combined toxoid (DT) induced anti-Aβantibodies, and the prior immunization with conventional DT vaccine enhanced the immunogenicity of the peptide. Cynomolgus monkeys were given the peptide vaccine subcutaneously in combination with the prior DT vaccination. Vaccination with a similar regimen was also performed on guinea pigs. The peptide vaccine induced anti-Aβantibodies in cynomolgus monkeys and guinea pigs without chemical adjuvants, and excessive immune responses were not observed. Those antibodies could preferentially recognize Aβ40, and Aβ42compared to Aβfibrils. The levels of serum anti-Aβantibodies and plasma Aβpeptides increased in both animals and decreased the brain Aβ40level of guinea pigs. The peptide vaccine could induce a similar binding profile of anti-Aβantibodies in cynomolgus monkeys and guinea pigs. The peptide vaccination could be expected to reduce the brain Aβpeptides and their toxic effects via clearance of Aβpeptides by generated antibodies.

scholarly journals SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies

2021 ◽  
Author(s):  
Yury Valdes-Balbin ◽  
Darielys Santana-Mederos ◽  
Lauren Quintero ◽  
Sonsire Fernández ◽  
Laura Rodriguez ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Tetanus Toxoid ◽  
Preclinical Studies

scholarly journals Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adults

npj Vaccines ◽  
2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Christine M. Oshansky ◽  
◽  
James King ◽  
Di Lu ◽  
James Zhou ◽  
...  
Keyword(s):  
Influenza A ◽  
Study Groups ◽  
Cross Reactivity ◽  
Healthy Adults ◽  
Response Strategy ◽  
Seroprotection Rate ◽  
Highly Pathogenic ◽  
Homologous Virus ◽  
Human Infections ◽  
Epidemic Wave

AbstractAn unprecedented number of human infections with avian influenza A(H7N9) in the fifth epidemic wave during the winter of 2016–2017 in China and their antigenic divergence from the viruses that emerged in 2013 prompted development of updated vaccines for pandemic preparedness. We report on the findings of a clinical study in healthy adults designed to evaluate the safety and immunogenicity of three dose levels of recombinant influenza vaccine derived from highly pathogenic A/Guangdong/17SF003/2016 (H7N9) virus adjuvanted with AS03 or MF59 oil-in water emulsions. Most of the six study groups meet the FDA CBER-specified vaccine licensure criterion of 70% seroprotection rate (SPR) for hemagglutination inhibition antibodies to the homologous virus. A substantial proportion of subjects show high cross-reactivity to antigenically distinct heterologous A(H7N9) viruses from the first epidemic wave of 2013. These results provide critical information to develop a pandemic response strategy and support regulatory requirements for vaccination under Emergency Use Authorization.

Quantitative Analysis of IgA-Subclass Antibodies Against Tetanus Toxoid

1995 ◽  
Vol 16 (3) ◽  
pp. 231-245 ◽  
Author(s):  
Per-Erik Engström ◽  
Silvia Nava ◽  
Shouji Mochizuki ◽  
Gunilla Norhagen E.
Keyword(s):  
Quantitative Analysis ◽  
Tetanus Toxoid
Sign in / Sign up

Export Citation Format

Share Document